With EU regulatory approval in the bag and US regulatory scrutiny expected to clear in the coming weeks, the €55bn AbbVie and Allergan merger should start in earnest in February or March.

Allergan forecasts 2019 revenue below expectations on looming competition for some of its top drugs and has shelved plans to sell its women’s health business.